Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label single-arm study of intravenous human immunoglobulin (10%) for primary immune thrombocytopenia
CTR20242765Phase 3Terminated
- Sponsor
- Sichuan Yuanda Shuyang Pharmaceutical
- Start
- Aug 2024
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of human immunoglobulin (pH 4) for intravenous injection in immune thrombocytopenia (ITP), sponsored by Sichuan Yuanda Shuyang Pharmaceutical. Started Aug 2024; status: terminated.
02
Drugs
human immunoglobulin (pH 4) for intravenous injection
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20242765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242765.